Echinocandins: a wealth of choice--how clinically different are they?

Published

Journal Article (Review)

PURPOSE OF REVIEW: The recent decade has been a 'golden age' for antifungal therapy. The introduction of a novel class of antifungals, the echinocandins, has revolutionized the therapy for invasive candidiasis, provided increasing options for antifungal prophylaxis in high-risk patients and energized the debate regarding combination antifungal therapy for invasive mycoses. RECENT FINDINGS: Randomized, controlled data exist for each echinocandin in the treatment of invasive candidiasis, and experts largely believe the agents to be equivalent in this setting. Future trials of combined echinocandin-triazole therapy for invasive aspergillosis are desired. Additionally, maximal dosing limitations are being pursued. SUMMARY: The echinocandins as a class offer an advance in the treatment of invasive candidiasis, an additional option for prophylaxis and an attractive choice for the study of combination antifungal therapy. Particularly for the major indication (treatment of invasive candidiasis), major clinical differences between agents have not been noted.

Full Text

Duke Authors

Cited Authors

  • Zaas, AK

Published Date

  • August 2008

Published In

Volume / Issue

  • 21 / 4

Start / End Page

  • 426 - 432

PubMed ID

  • 18594297

Pubmed Central ID

  • 18594297

Electronic International Standard Serial Number (EISSN)

  • 1473-6527

International Standard Serial Number (ISSN)

  • 0951-7375

Digital Object Identifier (DOI)

  • 10.1097/qco.0b013e328307c79c

Language

  • eng